Author(s) :

Aiman Irfan, Muhammad Faizan , Javeria, Tasawar Iqbal, Sidra Altaf.

Volume/Issue :

Abstract :

Rheumatoid arthritis (RA) is an autoimmune disorder that results in inflamed joints and gradually destroys cartilage over time. The pharmacological diversity has shown a number of advancements over the years that have effectively led to a transformation in management, producing better outcomes for people in terms of quality of life. The former is still being treated first with conventional disease-modifying antirheumatic drugs, of which methotrexate is the most commonly used biologic DMARDs based on TNF inhibitions and IL-6 blockers have provided targeted immunosuppression. Developments in new drug delivery systems have focused on nanoparticles and lipid-based carriers to reduce first-pass metabolism and minimize systemic side effects. The most recent discoveries in research dealing with medicinal plants and natural products showing some anti-inflammatory activity have opened up a new window of opportunity for adjuvant therapy. The perspectives of RA treatment, mainly emphasizing areas of precision medicine and novel drug delivery systems.

No. of Downloads :

2